Kawauchi K, Furuya S, Hirata K, Katoh C, Manabe O, Kobayashi K, Watanabe S, Shiga T. A convolutional neural network-based system to classify patients using FDG PET/CT examinations. BMC Cancer. 202003; 20(1):227.
Takahashi Y, Hosokawa S, Tsujiguchi T, Monzen S, Kanzaki T, Shirakawa K, Nemoto A, Ishimura H, Oriuchi N. Time‑related study on external exposure dose of 2‑deoxy‑2‑[F‑18]fluoro‑d‑glucose PET for workers’ safety. Radiological Physics and Technology. 202003; 13(1):98-103.
Kudo T, Inano A, Midorikawa S, Kubo H, Hayashi K, Nakashima S, Fukushima C, Maeda K, Oriuchi N, Irie S, Yamashita S, Kusuhara H. Determination of the Kinetic Parameters for 123I Uptake by the Thyroid, Thyroid Weights, and Thyroid Volumes in Present-day Healthy Japanese Volunteers. Health Physics. 202004; 118(4):417-426.
Oriuchi N, Aoki M, Ukon N, Washiyama K, Tan C, Shimoyama S, Nishijima KI, Takahashi K, Ito H, Ikezoe T, Zhao S. Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody. Scientific Reports. 202004; 10(1):6810.
Endoh H, Yamamoto R, Ichikawa A, Shiozawa S, Nishizawa N, Satoh Y, Oriuchi N. Clinicopathological significance of false-positive lymph node status on 18F-FDG PET in lung cancer. Clin Lung Cancer. Published: May 14, 2020. doi.org/10.1016/j.cllc.2020.05.002
Sugawara S, Ishii S, Kojima Y, Ito H, Suzuki Y, Oriuchi N. Feasibility of gamma camera-based GFR measurement using renal depth evaluated by lateral scan of 99mTc-DTPA renography. Annals of Nuclear Medicine. 202005; 34(5):349-357.
Sakaguchi M, Aikawa M, Saito M, Ukon N, Komori Y, Haba H. Activation cross section measurement of the deuteron-induced reaction on yttrium-89 for zirconium-89 production. Nuclear Instruments and Methods in Physics Research, Section B. 202006; 472:59-63.
Hata H, Kitao T, Sato J, Asaka T, Ohga N, Imamachi K, Hirata K, Shiga T, Yamazaki Y, Kitagawa Y. Monitoring indices of bone inflammatory activity of the jaw using SPECT bone scintigraphy: a study of ARONJ patients. Scientific Reports. 202007; 10(1):11385.
Kobayashi K, Manabe O, Hirata K, Yamaguchi S, Kobayashi H, Terasaka S, Toyonaga T, Furuya S, Magota K, Kuge Y, Kudo K, Shiga T, Tamaki N. Influence of the scan time point when assessing hypoxia in 18F-fluoromisonidazole PET: 2 vs. 4 h. European Journal of Nuclear Medicine and Molecular Imaging. 202007; 47(8):1833-1842.
Watanabe S, Nishijima KI, Okamoto S, Magota K, Hirata K, Toyonaga T, Shiga T, Kuge Y, Tamaki N. Biodistribution and internal radiation dosimetry of a novel probe for thymidine phosphorylase imaging, [123I]IIMU, in healthy volunteers. Annals of Nuclear Medicine. 202008; 34(8):595-599.
Takács S, Aikawa M, Haba H, Komori Y, Ditrói F, Szűcs Z, Saito M, Murata T, Sakaguchi M, Ukon N. Cross sections of alpha-particle induced reactions on natNi: Production of 67Cu. Nuclear Instruments and Methods in Physics Research, Section B. 202009; 479:125-136.
Ukon N, Zhao S, Washiyama K, Oriuchi N, Tan C, Shimoyama S, Aoki M, Kubo H, Takahashi K, Ito H. Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice. EJNMMI Physics. 202009; 7(1):58.
Hata H, Kitao T, Sato J, Asaka T, Imamachi K, Miyakoshi M, Hirata K, Magota K, Munakata Y, Shiga T, Yamazaki Y, Kitagawa Y. Quantitative bone single photon emission computed tomography analysis of the effects of duration of bisphosphonate administration on the parietal bone. Scientific Reports. 202010; 10(1):17461.
Magota K, Numata N, Shinyama D, Katahata J, Munakata Y, Maniawski PJ, Kobayashi K, Manabe O, Hirata K, Tateishi U, Kudo K, Shiga T. Halo artifacts of indwelling urinary catheter by inaccurate scatter correction in 18F-FDG PET/CT imaging: incidence, mechanism, and solutions. EJNMMI Physics. 202011; 7(1):66.
Ishii S, Sugawara S, Yaginuma Y, Kobiyama H, Hiruta M, Watanabe H, Yamakuni R, Hakozaki M, Fujimaki H, Ito H. Causes of false negatives in technetium-99m methoxyisobutylisonitrile scintigraphy for hyperparathyroidism: influence of size and cysts in parathyroid lesions. Annals of Nuclear Medicine. 202012; 34(12):892-898.
Aoki M, Zhao S, Takahashi K, Washiyama K, Ukon N, Tan C, Shimoyama S, Nishijima KI, Ogawa K. Preliminary Evaluation of Astatine-211-Labeled Bombesin Derivatives for Targeted Alpha Therapy. Chemical & Pharmaceutical Bulletin. 2020; 68(6):538-545.
Endoh H, Ichikawa A, Yamamoto R, Shiozawa S, Nishizawa N, Satoh Y, Oriuchi N. Prognostic impact of preoperative FDG-PET positive lymph nodes in lung cancer. Int J Clin Oncol 26: 87-94, 2020, DOI 10.1007/s10147-020-01783-x
Matsusaka Y, Nakahara T, Takahashi K, Iwabuchi Y, Nakamura S, Jinzaki M. Development of 68Ga-labeled tin colloids for evaluating phagocytic function of Kupffer cells using preclinical PET imaging. *Ann Nucl Med*, 34(11), 807-814, 2020
Oriuchi N, Sugawara S, Shiga T. Positron Emission Tomography for Response Evaluation in Microenvironment-Targeted Anti-Cancer Therapy. Biomedicines. 202009; 8(9):371.
Case Reports
Zhao J, Nan G, Shen G, Zhao S, Ito H. Bilateral medial medullary infarction accompanied by cerebral watershed infarction: A case report. Journal of Radiology Case Reports. 202004; 14(4):1-7.
Yoshinaga K, Zhao S, Washino K, Aoki M, Nishijima K, Shimoyama S, Ukon N, Gao F, Washiyama K, Ito N, Yoshioka N, Tamura N, Takahashi K, Ito H, Higashi T. Effects of alpha-emitting meta-211At-astato-benzylguanidine (211At-MABG) compared to 131I-meta-iodobenzylguanidine (131I-MIBG) on tumor growth suppression in a pheochromocytoma mouse model. 2020第102回米国内分泌学会議; 20200328-31; Web.
Oriuchi N, Aoki M, Ukon N, Washiyama K, Shimoyama S, Nishijima K, Takahashi K, Ito H, Ikezoe K, Zhao S. Stem cells-targeted radioimmunotherapy for acute myelogenous leukemia with 211At-labeled anti-CXCR4 monoclonal antibody. 2020米国核医学・分子イメージング学会; 20200711-14; Web.
Ito H, Kubo H, Takahashi K, Ishii S. Measurement of cerebral circulation and oxygen metabolism using integrated PET/MRI scanner with oxygen-15 labeled gases: Effects of attenuation correction and real-time motion correction. SNMMI 2020 Annual Meeting; 20200711-14; Web. Journal of Nuclear Medicine. 61(Suppl.1):75.
Washiyama K, Sugiyama A, Zhao S, Tatsumi T, Aoki M, Yamatsugu K, Nishijima K, Ukon N, Shimoyama S, Tan C, Oriuchi N, Takahashi K, Kanai M, Kodama T. Development of a low immunogenic mutated streptavidin pretargeting strategy with 211At labeled modified biotin for advanced cancer treatment. 2020米国核医学・分子イメージング学会; 20200711-14; Web.
Washino K, Zhao S, Yoshinaga K, Ito Y, Aoki M, Ukon N, Shimoyama S, Nishijima K, Washiyama K, Ito N, Yoshioka N, Tamura N, Takahashi K, Ito H, Higashi T. Differences and similarities in biodistribution, pharmacokinetics and metabolites of 211At-MABG versus 123I-MIBG in normal mice. 2020米国核医学・分子イメージング学会; 20200711-14; Web.
Zhao S, Yoshinaga K, Washino K, Aoki M, Nishijima K, Shimoyama S, Ukon N, Gao F, Washiyama K, Ito N, Yoshioka N, Tamura N, Takahashi K, Higashi T, Ito H. Effects and safety of alpha-emitting meta-211At-astato-benzylguanidine (211At-MABG) compared with 131I-meta-iodobenzylguanidine (131I-MIBG) on tumor growth suppression in a pheochromocytoma mouse model. 2020米国核医学・分子イメージング学会; 20200711-14; Web.
Oriuchi N, Zhao S, Aoki M, Tan C, Shimoyama S, Nishijima K, Washiyama K, Takahashi K, Sugawara S, Ito H, Ikezoe T. Preclinical evaluation of cancer stem cell targeted therapy with 211At-labeled anti-CXCR4 antibody. 日本放射線影響学会第63回大会; 20201015-16; 福島.
Zhao S, Ukon N, Yoshinaga K, Washino K, Aoki M, Nishijima K, Shimoyama S, Tan C, Washiyama K, Oriuchi N, Ito N, Yoshioka N, Tamura N, Takahashi K, Higashi T, Ito H. 正常マウスにおける211At-MABG と123I-MIBGの放射線線量の比較評価. 日本放射線影響学会第63回大会; 20201015-17; 福島.
Oriuchi N, Yamamoto R, Ichikawa A, Shiozawa S, Nishizawa N, Satoh Y, Endoh H. Prognostic significance of false-positive lymph node on 18F-FDG PET in lung cancer -Clinicopathological study-. 第58回日本癌治療学会学術集会; 20201022-24; 京都.
Ukon N, Washiyama K, Sugiyama A, Zhao S, Tatsumi T, Aoki M, Yamatsugu K, Nishijima K, Shimoyama S, Tan C, Joho T, Oriuchi N, Kanai M, Takahashi K, Kodama T. Biodistribution and dosimetry studies for optimization of pre-targeted radionuclide therapy in 211At labeled modified biotin. EANM 2020; 20201022-30; Web.
Washiyama K, Tatsumi T, Zhao S, Sugiyama A, Aoki M, Yamatsugu K, Ukon N, Nishijima K, Shimoyama S, Tan C, Joho T, Oriuchi N, Kanai M, Takahashi K, Kodama T. Search for the optimal bis-iminobiotin for the pretargeting strategy using a mutated low immunogenic streptavidin. EANM 2020; 20201022-30; Web.
Zhao S, Sugiyama A, Ukon N, Shimoyama S, Tatsumi T, Aoki M, Gao F, Yamatsugu K, Nishijima K, Joho T, Oriuchi N, Takahashi K, Kanai M, Kodama T, Washiyama K. Evaluation of therapeutic effect of the targeted alpha therapy using Cupid-211At-labeled Psyche-B pretargeting system in a human gastric cancer cell xenograft. EANM 2020; 20201022-30; Web.
Yoshinaga K, Zhao S, Washino K, Aoki M, Nishijima K, Shimoyama S, Ukon N, Gao F, Washiyama K, Ito N, Yoshioka N, Tamura N, Takahashi K, Higashi T, Ito H. 褐色細胞腫モデルにおける211At-MABGと131I-MIBGの抗腫瘍効果および安全性の比較. 第60回日本核医学会学術総会; 20201112-14; 神戸.
Zhao S, Sugiyama A, Shimoyama S, Tatsumi T, Ukon N, Gao F, Aoki M, Yamatsugu K, Takahashi K, Kanai M, Washiyama K. ヒト胃癌細胞移植担癌モデル動物におけるドラッグデリバリーシステム（Cupid-Psycheシステム）を用いたアルファ線の治療効果. 第60回日本核医学会学術総会; 20201112-14; 神戸.
Tatsumi T, Yamatsugu K, Sugiyama A, Zhao S, Aoki M, Nishijima K, Ukon N, Shimoyama S, Tan C, Gao F, Joho T, Oriuchi N, Takahashi K, Kanai M, Kodama T, Washiyama K. Targeted delivery of 211At with low immunogenic mutant streptavidin–bisiminobiotin pre-targeting system. Pacifichem2020; 20201216-21; Honolulu, USA.
